Study discontinued based on planned interim analysis of the primary endpoint. Not linked to any safety concern.

Primary Objective:

To assess the long-term safety of vatelizumab in MS patients

Secondary Objective:

To assess the long-term efficacy of vatelizumab

The maximum study duration per patient will be 192 weeks, including a Treatment Period of 96 weeks and Post-treatment Safety Follow-up Period of 96 weeks.

Inclusion criteria:

Patients who completed the 12-week treatment period in DRI13839.

Exclusion criteria:

• Any clinically significant or ongoing adverse events, or laboratory abnormalities from DRI13839 that per Investigator judgment would adversely affect the patient's participation in the long-term extension study.
• Confirmed platelet count below the lower limit of normal at any time during DRI13839.
• Pregnancy or breast-feeding.
• Other protocol defined exclusion criteria may apply.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.